Bausch + Lomb Corporation (NYSE: BLCO) Stock Competitors & Peer Comparison
See BLCO's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BLCO and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BLCO | $19.99 | +0.35% | 7.1B | 30.72 | $0.65 | N/A |
| ISRG | $452.80 | -3.36% | 160B | 47.07 | $9.62 | N/A |
| BDX | $211.88 | -0.78% | 57.7B | 16.30 | $13.00 | +1.88% |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +1.88% |
| MDLN | $39.64 | -0.30% | 34.8B | 29.06 | $1.36 | N/A |
| RMD | $235.30 | -1.68% | 33.1B | 20.40 | $11.53 | +1.06% |
| WST | $399.81 | +1.87% | 27.9B | 43.48 | $9.20 | +0.22% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $90.38 | +3.67% | 15.4B | 12.73 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +1.88% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
BLCO vs ISRG Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, ISRG has a market cap of 160B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while ISRG trades at $452.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas ISRG's P/E ratio is 47.07. In terms of profitability, BLCO's ROE is -0.02%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, BLCO is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDX)
BLCO vs BDX Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, BDX has a market cap of 57.7B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while BDX trades at $211.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas BDX's P/E ratio is 16.30. In terms of profitability, BLCO's ROE is -0.02%, compared to BDX's ROE of +0.04%. Regarding short-term risk, BLCO is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check BDX's competition here
Becton, Dickinson and Company (NYSE: BDXA)
BLCO vs BDXA Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas BDXA's P/E ratio is 45.70. In terms of profitability, BLCO's ROE is -0.02%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, BLCO is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check BDXA's competition here
Medline Inc. (NASDAQ: MDLN)
BLCO vs MDLN Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, MDLN has a market cap of 34.8B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while MDLN trades at $39.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas MDLN's P/E ratio is 29.06. In terms of profitability, BLCO's ROE is -0.02%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, BLCO is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check MDLN's competition here
ResMed Inc. (NYSE: RMD)
BLCO vs RMD Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, RMD has a market cap of 33.1B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while RMD trades at $235.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas RMD's P/E ratio is 20.40. In terms of profitability, BLCO's ROE is -0.02%, compared to RMD's ROE of +0.25%. Regarding short-term risk, BLCO is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check RMD's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
BLCO vs WST Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, WST has a market cap of 27.9B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while WST trades at $399.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas WST's P/E ratio is 43.48. In terms of profitability, BLCO's ROE is -0.02%, compared to WST's ROE of +0.21%. Regarding short-term risk, BLCO is less volatile compared to WST. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
BLCO vs HOLX Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas HOLX's P/E ratio is 31.54. In terms of profitability, BLCO's ROE is -0.02%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, BLCO is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
BLCO vs SOLV Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, SOLV has a market cap of 15.4B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while SOLV trades at $90.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas SOLV's P/E ratio is 12.73. In terms of profitability, BLCO's ROE is -0.02%, compared to SOLV's ROE of +0.03%. Regarding short-term risk, BLCO is less volatile compared to SOLV. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
BLCO vs BDXB Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas BDXB's P/E ratio is 7.60. In terms of profitability, BLCO's ROE is -0.02%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, BLCO is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
BLCO vs BAX Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, BAX has a market cap of 13.3B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while BAX trades at $25.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas BAX's P/E ratio is 12.39. In terms of profitability, BLCO's ROE is -0.02%, compared to BAX's ROE of -0.12%. Regarding short-term risk, BLCO is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check BAX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
BLCO vs COO Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, COO has a market cap of 11.9B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while COO trades at $62.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas COO's P/E ratio is 13.67. In terms of profitability, BLCO's ROE is -0.02%, compared to COO's ROE of +0.07%. Regarding short-term risk, BLCO is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check COO's competition here
Repligen Corporation (NASDAQ: RGEN)
BLCO vs RGEN Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, RGEN has a market cap of 11.1B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while RGEN trades at $173.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas RGEN's P/E ratio is 96.38. In terms of profitability, BLCO's ROE is -0.02%, compared to RGEN's ROE of -0.01%. Regarding short-term risk, BLCO is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check RGEN's competition here
Avantor, Inc. (NYSE: AVTR)
BLCO vs AVTR Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, AVTR has a market cap of 10.5B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while AVTR trades at $15.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas AVTR's P/E ratio is 18.19. In terms of profitability, BLCO's ROE is -0.02%, compared to AVTR's ROE of +0.06%. Regarding short-term risk, BLCO is less volatile compared to AVTR. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check AVTR's competition here
AptarGroup, Inc. (NYSE: ATR)
BLCO vs ATR Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, ATR has a market cap of 9B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while ATR trades at $142.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas ATR's P/E ratio is 24.92. In terms of profitability, BLCO's ROE is -0.02%, compared to ATR's ROE of +0.10%. Regarding short-term risk, BLCO is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check ATR's competition here
Teleflex Incorporated (NYSE: TFX)
BLCO vs TFX Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, TFX has a market cap of 6.4B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while TFX trades at $150.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas TFX's P/E ratio is 17.22. In terms of profitability, BLCO's ROE is -0.02%, compared to TFX's ROE of +0.10%. Regarding short-term risk, BLCO is less volatile compared to TFX. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
BLCO vs MMSI Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, MMSI has a market cap of 5.2B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while MMSI trades at $87.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas MMSI's P/E ratio is 22.30. In terms of profitability, BLCO's ROE is -0.02%, compared to MMSI's ROE of +0.10%. Regarding short-term risk, BLCO is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
BLCO vs ICUI Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, ICUI has a market cap of 4.3B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while ICUI trades at $172.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas ICUI's P/E ratio is 21.53. In terms of profitability, BLCO's ROE is -0.02%, compared to ICUI's ROE of +0.03%. Regarding short-term risk, BLCO is less volatile compared to ICUI. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check ICUI's competition here
Envista Holdings Corp (NYSE: NVST)
BLCO vs NVST Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, NVST has a market cap of 4B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while NVST trades at $25.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas NVST's P/E ratio is 17.13. In terms of profitability, BLCO's ROE is -0.02%, compared to NVST's ROE of +0.21%. Regarding short-term risk, BLCO is less volatile compared to NVST. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
BLCO vs PLSE Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, PLSE has a market cap of 3.8B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while PLSE trades at $53.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas PLSE's P/E ratio is -45.08. In terms of profitability, BLCO's ROE is -0.02%, compared to PLSE's ROE of -0.78%. Regarding short-term risk, BLCO is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check PLSE's competition here
Stevanato Group S.p.A. (NYSE: STVN)
BLCO vs STVN Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, STVN has a market cap of 3.7B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while STVN trades at $13.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas STVN's P/E ratio is 20.50. In terms of profitability, BLCO's ROE is -0.02%, compared to STVN's ROE of +0.09%. Regarding short-term risk, BLCO is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check STVN's competition here
AtriCure, Inc. (NASDAQ: ATRC)
BLCO vs ATRC Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, ATRC has a market cap of 3B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while ATRC trades at $58.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas ATRC's P/E ratio is 1817.08. In terms of profitability, BLCO's ROE is -0.02%, compared to ATRC's ROE of +0.03%. Regarding short-term risk, BLCO is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check ATRC's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
BLCO vs BLFS Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, BLFS has a market cap of 1.9B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while BLFS trades at $38.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas BLFS's P/E ratio is 37.49. In terms of profitability, BLCO's ROE is -0.02%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, BLCO is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check BLFS's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
BLCO vs XRAY Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, XRAY has a market cap of 1.9B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while XRAY trades at $9.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas XRAY's P/E ratio is 6.62. In terms of profitability, BLCO's ROE is -0.02%, compared to XRAY's ROE of -0.09%. Regarding short-term risk, BLCO is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
BLCO vs LMAT Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, LMAT has a market cap of 1.9B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while LMAT trades at $80.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas LMAT's P/E ratio is 29.76. In terms of profitability, BLCO's ROE is -0.02%, compared to LMAT's ROE of +0.15%. Regarding short-term risk, BLCO is less volatile compared to LMAT. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check LMAT's competition here
Azenta, Inc. (NASDAQ: AZTA)
BLCO vs AZTA Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, AZTA has a market cap of 1.7B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while AZTA trades at $39.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas AZTA's P/E ratio is 93.33. In terms of profitability, BLCO's ROE is -0.02%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, BLCO is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
BLCO vs KMTS Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, KMTS has a market cap of 1.7B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while KMTS trades at $28.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas KMTS's P/E ratio is -10.86. In terms of profitability, BLCO's ROE is -0.02%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, BLCO is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
BLCO vs STAA Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, STAA has a market cap of 1.3B. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while STAA trades at $25.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas STAA's P/E ratio is 44.23. In terms of profitability, BLCO's ROE is -0.02%, compared to STAA's ROE of +0.00%. Regarding short-term risk, BLCO is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
BLCO vs ATRI Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas ATRI's P/E ratio is 64.50. In terms of profitability, BLCO's ROE is -0.02%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, BLCO is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check ATRI's competition here
MiniMed Group, Inc. (NASDAQ: MMEDV)
BLCO vs MMEDV Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, MMEDV has a market cap of 495.6M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while MMEDV trades at $17.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas MMEDV's P/E ratio is N/A. In terms of profitability, BLCO's ROE is -0.02%, compared to MMEDV's ROE of N/A. Regarding short-term risk, BLCO is more volatile compared to MMEDV. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check MMEDV's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
BLCO vs ANGO Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, ANGO has a market cap of 493.1M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while ANGO trades at $11.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas ANGO's P/E ratio is -30.06. In terms of profitability, BLCO's ROE is -0.02%, compared to ANGO's ROE of -0.19%. Regarding short-term risk, BLCO is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check ANGO's competition here
Embecta Corp. (NASDAQ: EMBC)
BLCO vs EMBC Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, EMBC has a market cap of 350M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while EMBC trades at $6.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas EMBC's P/E ratio is 2.38. In terms of profitability, BLCO's ROE is -0.02%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, BLCO is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check EMBC's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
BLCO vs SMTI Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, SMTI has a market cap of 289.9M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while SMTI trades at $31.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas SMTI's P/E ratio is -525.83. In terms of profitability, BLCO's ROE is -0.02%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, BLCO is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check SMTI's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
BLCO vs OSUR Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, OSUR has a market cap of 237.9M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while OSUR trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas OSUR's P/E ratio is -5.00. In terms of profitability, BLCO's ROE is -0.02%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, BLCO is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check OSUR's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
BLCO vs UTMD Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, UTMD has a market cap of 230.4M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while UTMD trades at $72.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas UTMD's P/E ratio is 21.48. In terms of profitability, BLCO's ROE is -0.02%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, BLCO is less volatile compared to UTMD. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
BLCO vs PDEX Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, PDEX has a market cap of 201M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while PDEX trades at $63.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas PDEX's P/E ratio is 17.21. In terms of profitability, BLCO's ROE is -0.02%, compared to PDEX's ROE of +0.26%. Regarding short-term risk, BLCO is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check PDEX's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
BLCO vs NNNN Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, NNNN has a market cap of 169M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while NNNN trades at $3.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas NNNN's P/E ratio is 25.67. In terms of profitability, BLCO's ROE is -0.02%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, BLCO is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check NNNN's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
BLCO vs KRMD Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, KRMD has a market cap of 141.7M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while KRMD trades at $3.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas KRMD's P/E ratio is -77.12. In terms of profitability, BLCO's ROE is -0.02%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, BLCO is less volatile compared to KRMD. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
BLCO vs STXS Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, STXS has a market cap of 111.2M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while STXS trades at $1.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas STXS's P/E ratio is -6.53. In terms of profitability, BLCO's ROE is -0.02%, compared to STXS's ROE of -1.33%. Regarding short-term risk, BLCO is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check STXS's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
BLCO vs AKYA Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas AKYA's P/E ratio is -1.34. In terms of profitability, BLCO's ROE is -0.02%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, BLCO is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check AKYA's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
BLCO vs POCI Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, POCI has a market cap of 53.8M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while POCI trades at $4.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas POCI's P/E ratio is -10.66. In terms of profitability, BLCO's ROE is -0.02%, compared to POCI's ROE of -0.24%. Regarding short-term risk, BLCO is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check POCI's competition here
SkyAI, Inc. (NASDAQ: STSS)
BLCO vs STSS Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas STSS's P/E ratio is -0.02. In terms of profitability, BLCO's ROE is -0.02%, compared to STSS's ROE of -1.54%. Regarding short-term risk, BLCO is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
BLCO vs OMIC Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas OMIC's P/E ratio is -0.58. In terms of profitability, BLCO's ROE is -0.02%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, BLCO is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
BLCO vs IGAP Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas IGAP's P/E ratio is -10.52. In terms of profitability, BLCO's ROE is -0.02%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, BLCO is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check IGAP's competition here
Daxor Corporation (NASDAQ: DXR)
BLCO vs DXR Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, DXR has a market cap of 49.4M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while DXR trades at $8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas DXR's P/E ratio is 6.88. In terms of profitability, BLCO's ROE is -0.02%, compared to DXR's ROE of +0.13%. Regarding short-term risk, BLCO is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check DXR's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
BLCO vs HBIO Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, HBIO has a market cap of 38.2M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while HBIO trades at $8.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas HBIO's P/E ratio is -23.31. In terms of profitability, BLCO's ROE is -0.02%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, BLCO is less volatile compared to HBIO. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check HBIO's competition here
Nephros, Inc. (NASDAQ: NEPH)
BLCO vs NEPH Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, NEPH has a market cap of 30.6M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while NEPH trades at $2.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas NEPH's P/E ratio is 46.92. In terms of profitability, BLCO's ROE is -0.02%, compared to NEPH's ROE of +0.17%. Regarding short-term risk, BLCO is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check NEPH's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
BLCO vs SDC Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas SDC's P/E ratio is -0.03. In terms of profitability, BLCO's ROE is -0.02%, compared to SDC's ROE of -1.96%. Regarding short-term risk, BLCO is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check SDC's competition here
Milestone Scientific Inc. (AMEX: MLSS)
BLCO vs MLSS Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, MLSS has a market cap of 27.5M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while MLSS trades at $0.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas MLSS's P/E ratio is -6.07. In terms of profitability, BLCO's ROE is -0.02%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, BLCO is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check MLSS's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
BLCO vs ZJYL Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, ZJYL has a market cap of 26.1M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while ZJYL trades at $3.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas ZJYL's P/E ratio is 22.78. In terms of profitability, BLCO's ROE is -0.02%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, BLCO is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check ZJYL's competition here
Invacare Corporation (NYSE: IVC)
BLCO vs IVC Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas IVC's P/E ratio is -0.79. In terms of profitability, BLCO's ROE is -0.02%, compared to IVC's ROE of -0.46%. Regarding short-term risk, BLCO is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
BLCO vs RVP Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, RVP has a market cap of 16.9M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while RVP trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas RVP's P/E ratio is -4.69. In terms of profitability, BLCO's ROE is -0.02%, compared to RVP's ROE of -0.05%. Regarding short-term risk, BLCO is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
BLCO vs BNGO Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, BNGO has a market cap of 13.5M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while BNGO trades at $1.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas BNGO's P/E ratio is -0.38. In terms of profitability, BLCO's ROE is -0.02%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, BLCO is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check BNGO's competition here
Femasys Inc. (NASDAQ: FEMY)
BLCO vs FEMY Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, FEMY has a market cap of 11.6M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while FEMY trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas FEMY's P/E ratio is -0.31. In terms of profitability, BLCO's ROE is -0.02%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, BLCO is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check FEMY's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
BLCO vs RGNT Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, RGNT has a market cap of 8.1M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while RGNT trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas RGNT's P/E ratio is -0.47. In terms of profitability, BLCO's ROE is -0.02%, compared to RGNT's ROE of N/A. Regarding short-term risk, BLCO is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check RGNT's competition here
Lucyd, Inc (NASDAQ: LUCY)
BLCO vs LUCY Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, LUCY has a market cap of 7.2M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while LUCY trades at $0.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas LUCY's P/E ratio is -0.64. In terms of profitability, BLCO's ROE is -0.02%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, BLCO is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
BLCO vs NSTG Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas NSTG's P/E ratio is -0.03. In terms of profitability, BLCO's ROE is -0.02%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, BLCO is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check NSTG's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
BLCO vs CUPR Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, CUPR has a market cap of 4.8M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while CUPR trades at $1.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas CUPR's P/E ratio is -1.31. In terms of profitability, BLCO's ROE is -0.02%, compared to CUPR's ROE of -0.85%. Regarding short-term risk, BLCO is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check CUPR's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
BLCO vs POAI Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas POAI's P/E ratio is -0.38. In terms of profitability, BLCO's ROE is -0.02%, compared to POAI's ROE of -21.19%. Regarding short-term risk, BLCO is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
BLCO vs MHUA Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas MHUA's P/E ratio is 0.25. In terms of profitability, BLCO's ROE is -0.02%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, BLCO is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
BLCO vs GMVD Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas GMVD's P/E ratio is -0.01. In terms of profitability, BLCO's ROE is -0.02%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, BLCO is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
BLCO vs GMVDW Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas GMVDW's P/E ratio is N/A. In terms of profitability, BLCO's ROE is -0.02%, compared to GMVDW's ROE of +3.68%. Regarding short-term risk, BLCO is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check GMVDW's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
BLCO vs NXGL Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, NXGL has a market cap of 1.7M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while NXGL trades at $3.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas NXGL's P/E ratio is -5.01. In terms of profitability, BLCO's ROE is -0.02%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, BLCO is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check NXGL's competition here
Avinger, Inc. (NASDAQ: AVGR)
BLCO vs AVGR Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas AVGR's P/E ratio is -0.05. In terms of profitability, BLCO's ROE is -0.02%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, BLCO is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
BLCO vs NXGLW Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, NXGLW has a market cap of 496.3K. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas NXGLW's P/E ratio is -0.01. In terms of profitability, BLCO's ROE is -0.02%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, BLCO is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
BLCO vs LUCYW Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas LUCYW's P/E ratio is N/A. In terms of profitability, BLCO's ROE is -0.02%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, BLCO is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for BLCO.Check LUCYW's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
BLCO vs ATRS Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas ATRS's P/E ratio is 14.95. In terms of profitability, BLCO's ROE is -0.02%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, BLCO is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check ATRS's competition here
IntriCon Corporation (NASDAQ: IIN)
BLCO vs IIN Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, IIN has a market cap of 0. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas IIN's P/E ratio is 226.45. In terms of profitability, BLCO's ROE is -0.02%, compared to IIN's ROE of -0.00%. Regarding short-term risk, BLCO is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check IIN's competition here
Invuity, Inc. (NASDAQ: IVTY)
BLCO vs IVTY Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas IVTY's P/E ratio is -3.80. In terms of profitability, BLCO's ROE is -0.02%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, BLCO is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check IVTY's competition here
Apria, Inc. (NASDAQ: APR)
BLCO vs APR Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, APR has a market cap of 0. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas APR's P/E ratio is 22.59. In terms of profitability, BLCO's ROE is -0.02%, compared to APR's ROE of +9.81%. Regarding short-term risk, BLCO is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check APR's competition here
Analogic Corporation (NASDAQ: ALOG)
BLCO vs ALOG Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas ALOG's P/E ratio is 40.93. In terms of profitability, BLCO's ROE is -0.02%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, BLCO is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check ALOG's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
BLCO vs HRC Comparison November 2026
Bausch + Lomb Corporation (NYSE: BLCO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLCO stands at 7.1B. In comparison, HRC has a market cap of 0. Regarding current trading prices, BLCO is priced at $19.99 on the NYSE, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLCO currently has a P/E ratio of 30.72, whereas HRC's P/E ratio is 41.92. In terms of profitability, BLCO's ROE is -0.02%, compared to HRC's ROE of +0.14%. Regarding short-term risk, BLCO is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for BLCO.Check HRC's competition here